Travoprost-Optik, eye drops 0.004% 5 ml

Antiglaucoma drug – prostaglandin F2-alpha analogue synthetic.

Travoprost is absorbed through the cornea, where hydrolysis of travoprost to the biologically active form – acid travoprost occurs. Cmax of hervoprost in blood plasma is reached within 30 minutes after topical application and is 25 pg/ml or less.

Travoprost is rapidly eliminated from plasma, within an hour the concentration is reduced below the detection threshold.

Pharmacodynamics

Indications

Active ingredient

Composition

1 ml:

How to take, the dosage

Special Instructions

A gradual change in eye color due to an increase in the amount of brown pigment in the iris may occur with use.

This effect occurs predominantly in patients with mixed iris coloration such as blue-brown, gray-brown, green-brown, or yellow-brown due to an increase in melanin in the stromal melanocytes of the iris.

Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris, and the entire iris or portions of the iris may become more intense brown.

In patients with uniformly blue, gray, green or brown colored eyes, changes in eye color after two years of use have been very rare. The color change was not accompanied by any clinical symptoms or pathological changes.

There has been no further increase in brown pigment after discontinuation of therapy, but the color change that has already developed may be irreversible.

People should be informed about the possibility of eye discoloration before starting treatment.

Treatment of only one eye may result in permanent heterochromia.

In the presence of nevi or lentigines on the iris, no change has been noted with the effects of travoprost.

Travoprost may cause darkening, thickening and lengthening of the eyelashes and/or an increase in their number; rarely, darkening of the eyelid skin.

It can be used in combination with other anti-ocupuncture drugs for topical use. In this case, the interval between their application should be at least 5 minutes.

If contact lenses are worn, they should be removed and replaced within 20 minutes after the procedure at the earliest before instillation.

Contraindications

Children and adolescents under 18 years of age, hypersensitivity to travoprost.

With caution use in the presence of risk factors for macular edema (aphakia, pseudophakia, damage of the posterior capsule of the lens), in acute iritis, uveitis.

Side effects

Visually: very often – transient mild conjunctival hyperemia, passing on its own; often – decreased visual acuity, discomfort and foreign body feeling, pain, itching, burning in the eyes, visual disorders, blepharitis, “fog” before the eyes, cataract, conjunctivitis, dry conjunctiva, iris discoloration, keratitis, crusting on the edges of the eyelids, photophobia, subconjunctival hemorrhage and increased tear production.

Cardiovascular system: often – increase or decrease of BP, bradycardia, angina pectoris, chest pain, hypercholesterolemia.

CNS disorders: frequently – general restlessness, headache, depression.

Urinary system disorders: often – urinary incontinence and urinary infections.

Muscular system disorders: often – arthritis, back pain.

Others: often – flu-like syndrome, sinusitis, bronchitis, dyspepsia.

Pregnancy use

Pregnancy is contraindicated.

There is no sufficient experience of use during lactation.

The use during breastfeeding is possible only under the supervision of a physician and only when the potential benefit of the therapy for the mother outweighs the possible risk of side effects for the breastfed child.

Similarities